Skip to content
Head to head

Mirum Pharmaceuticals vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: MIRM · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

MIRM +33.1%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
MIRMVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price96.13515.02
Change today+0.65%-1.08%
1-year return+39.0%+22.0%
Market cap$6.28B$130.58B
52-week range63.23 – 130.00412.27 – 568.67
Valuation
P/E (TTM)-6.6433.14
P/E percentile, own 5-yr range80th99th
P/B-115.826.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-0.4715.32
Net profit (TTM)$-30.68M$3.88B
Revenue (TTM)$670.78M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+39.6%+11.8%
Gross margin81.7%85.5%
Operating margin-21.6%33.1%
Net margin-134.8%30.7%
Free cash flow (TTM)$-308.85M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership114.9%96.8%
Insider activity (12mo)26 buy / 23 sell28 buy / 22 sell
Short interest (% of float)10.0%1.9%
Analyst consensus100% buy (12)95% buy / 5% hold (21)
Analyst price target$159 (+65%)$624 (+21%)
StockVane view
StockVane Quant RatingD (80)C (68)
Company
Employees3726,400
Founded20181989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.